collections_bookmark Part of Dominaria United
Negate card art
Live Play Data

Negate

{1} {U} · Instant · Teenage Mutant Ninja Turtles (TMT)
16%
Live Inclusion
Times Brought
2325
Decks Running
1236
Median Cast Turn
7.0
Drawn → Played
51%
Format

Negate sits in 16% of tracked Commander decks on Playgroup Live, is drawn 24% of the time, and reaches the stack on a median turn of 7.0. When it resolves, teams that cast it win at 29%.

Negate shows up in 16% of the 7624 Commander decks that have played a tracked game on Playgroup Live. That makes it one of the more common reactive pieces in blue, even in a format crowded with counterspell options at every price point. Across 2063 tracked games, it has been brought to the table 2328 times, drawn 567 times, and cast 290 times.

The draw-to-play rate sits at 51%. Negate is an instant held in hand until the right moment arrives, so a drawn copy that goes uncast frequently reflects a game that ended before the right target appeared, not a player choosing to pass. Median first cast lands on turn 7.0, consistent with a card that waits for the mid-game threat rather than being deployed on curve. The data here spans 907 distinct players, with no single contributor accounting for more than a small slice of instances, which gives the numbers reasonable breadth for a dataset of this size.

Blue is the natural home: every top commander in the list carries blue in its color identity. Negate slots cleanly into control, tempo, and combo shells that need cheap insurance against noncreature threats. It is legal in Commander, Duel Commander, Pauper Commander, and every other major sanctioned format.

At a glance
  • 16% of tracked Commander decks include Negate
  • 24% draw rate across tracked games
  • 51% of drawn Negates reach the stack before the game ends
  • T7.0 median first-cast turn, deep into the mid-game
  • 907 distinct players have brought Negate to a tracked game

First-cast turn

n=290
0%
T1
2%
T2
3%
T3
8%
T4
11%
T5
54%
T6-9
22%
T10+
Median 7.0 P25 6 · P75 9 · max 18
On curve 2% (5 / 290 cast on T2) Cast same turn as drawn 19%

The "good card" funnel

2328 brought · 907 players
Brought to game
2328
Ever drawn
567
Reached battlefield
290
Still on board at game end
21
51%

Of 2328 Negates brought to games, 567 were drawn, 290 of those were cast, and nearly all resolved to the graveyard as expected for an instant spell.

≥ +2.7pp

Players who cast this card win 29% of the time (n=276) , vs 21% when it never left the library (n=1521).

When players drew this card but left it in hand, they won 25% (n=249) — about the same as leaving it in the library. Those players survived long enough to draw it, so the gap above is about the card resolving, not just about surviving.

Observed gap +7.9pp; 95% confidence interval +2.7pp to +13.2pp. Correlational, not causal: powerful payoffs also get cast more often in games you are already winning.

Final zone distribution

641 instances
4.7%
Library
3.3%
Battlefield
49.0%
Graveyard
7.3%
Exile

Most Negate instances finish in the graveyard after resolving, with the library accounting for a small fraction of final zones. That graveyard-heavy profile is exactly what you expect from a high-volume instant that gets cast and forgotten rather than sitting stranded in a deck.

Commanders that played this card

in tracked games

The commander list spans at least ten distinct names across several color identities, all sharing blue. No single commander dominates, which suggests Negate is a broad blue staple rather than the pet card of one specific archetype.

Frequently Asked

How often is Negate drawn and cast in a Commander game?
Across 2063 tracked games, Negate was drawn 24% of the time it was in a deck. That is normal for a singleton in a 100-card format. Of the 567 copies that reached a hand, 51% were cast before the game concluded. Median first cast lands on turn 7.0, reflecting its role as a reactive piece held until a meaningful noncreature target appears.
What turn does Negate typically get cast?
Median first-cast turn is 7.0, with the distribution clustering between turns 5 and 9. The on-curve rate is very low, which is expected: Negate is almost never cast on turn 2 by design. Players hold it in hand and deploy it reactively, so the hand-to-cast delay is longer than you would see with a proactive spell. The same-turn cast rate reflects this pattern clearly.
Does casting Negate correlate with winning?
Games where Negate was cast show a win rate of 29%, compared to 21% in games where it stayed in the library and was never interacted with. The delta is a directional positive signal, but both sample sizes matter. With 276 observations in the cast bucket and 1521 in the library bucket, this is early-signal territory rather than a definitive conclusion.
Is Negate banned anywhere?
Negate is legal in Commander, Duel Commander, Pauper Commander, Oathbreaker, Standard, Pioneer, Modern, Legacy, Vintage, Pauper, Historic, Alchemy, Timeless, Gladiator, and Brawl. It is not legal in Old School or Premodern due to printing windows. There are no bans or restrictions on record for Negate in any current sanctioned format.
What commanders run Negate most often in this dataset?
The top commanders by raw deck count are spread across blue-inclusive identities: Grixis (UBR) and mono-blue shells dominate the top of the list. Fire Lord Azula, Sauron the Dark Lord, and Zndrsplt, Eye of Wisdom each appear in the most Negate decks tracked so far. The spread across ten different commanders at the top is a good sign that the data is not dominated by one archetype.
How reliable is this data given Playgroup Live's sample size?
Playgroup Live is a live-play dataset, not a decklist scraper. The 2063 tracked games here involve 907 distinct players, and no single player accounts for more than a small fraction of all instances. That spread is a meaningful strength for a dataset of this scale. Numbers should be read as directional signals. The cast-versus-library win-rate delta in particular carries a standard error that puts the lower confidence bound close to zero for the multiplayer view, so treat it as consistent with a benefit rather than proof of one.